Aurinia Pharmaceuticals Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Aurinia Pharmaceuticals Inc. (AUPH) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $103.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- Aurinia Pharmaceuticals Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $103.91M.
- Aurinia Pharmaceuticals Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$8.42M.
- Aurinia Pharmaceuticals Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$90.23M.
- Aurinia Pharmaceuticals Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$112.36M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $103.91M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$8.42M 10-K · filed 2026-02-26 |
| 2023-12-31 | -$90.23M 10-K · filed 2026-02-26 |
| 2022-12-31 | -$112.36M 10-K · filed 2025-02-27 |
| 2021-12-31 | -$180.37M 10-K · filed 2024-02-15 |
| 2020-12-31 | -$61.02M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$88.69M 10-K · filed 2022-02-28 |
| 2018-12-31 | -$53.29M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |